{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hu Z"],"funding":["National Natural Science Foundation of China","National Key Research and Development Program of China"],"pagination":["e0090325"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12455995"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["99(9)"],"pubmed_abstract":["Respiratory syncytial virus (RSV) is a global public health concern. Currently, RSV vaccines are approved only for use in older adults, while preventing the disease in infants and children, as well as ensuring vaccine durability, remains a significant challenge. The pre-fusion conformation of the RSV fusion (F) glycoprotein is a primary target for vaccine development, as it elicits significantly higher neutralizing antibody titers than the post-fusion form. Here, we conjugated either the first-generation RSV pre-fusion F antigen, DS-Cav1, or the second-generation antigen, Sc9-10, to a computationally designed nanoparticle platform, NPM, via a Catcher/Tag system. Conjugating RSV pre-fusion F to NPM significantly enhanced immunogenicity, stability, and bioactivity compared to display on the "],"journal":["Journal of virology"],"pubmed_title":["Nanoparticle vaccine based on the pre-fusion F glycoprotein of respiratory syncytial virus elicits robust protective immune responses."],"pmcid":["PMC12455995"],"funding_grant_id":["82025001","2024YFA0920001","2024YFA0920002","82495203"],"pubmed_authors":["Liu J","Yu R","Hu Z","Guo Y","Liu S","Zhang S","Zou Y","Wei P","Ding Y","Yao Y","Ren L","Wei R","Zhao D","Wang Y","Zhang C","Zhao J","Jin J","Mo X","Zhou P","Chen H","Zhou Y","Zhuang Z","Zang N","Deng C","Li Y","Peng G","Tian S","Jing C","Fu M","Liu E"],"additional_accession":[]},"is_claimable":false,"name":"Nanoparticle vaccine based on the pre-fusion F glycoprotein of respiratory syncytial virus elicits robust protective immune responses.","description":"Respiratory syncytial virus (RSV) is a global public health concern. Currently, RSV vaccines are approved only for use in older adults, while preventing the disease in infants and children, as well as ensuring vaccine durability, remains a significant challenge. The pre-fusion conformation of the RSV fusion (F) glycoprotein is a primary target for vaccine development, as it elicits significantly higher neutralizing antibody titers than the post-fusion form. Here, we conjugated either the first-generation RSV pre-fusion F antigen, DS-Cav1, or the second-generation antigen, Sc9-10, to a computationally designed nanoparticle platform, NPM, via a Catcher/Tag system. Conjugating RSV pre-fusion F to NPM significantly enhanced immunogenicity, stability, and bioactivity compared to display on the ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-07-15T05:46:52.169Z","creation":"2026-06-29T03:19:37.693Z"},"accession":"S-EPMC12455995","cross_references":{"pubmed":["40856491"],"doi":["10.1128/jvi.00903-25"]}}